CAGR: 9.80%Current Market Size: USD 2.87 billion Fastest Growing Region: APAC
Largest Market: North AmericaProjection Time: 2022-2028Base Year: 2021
Global buccal drug delivery systems are expected to reach USD 6.06 billion by 2028, at a CAGR of 9.80% from 2022 to 2028. The research and development regarding drug delivery systems have provided growth opportunities to the market. Buccal delivery systems are gaining popularity in most of the regions owing to the preference towards the buccal mode of delivery. Buccal delivery is effective as compared to the other administration modes as it is quickly absorbed. There are large investments in the buccal drug delivery systems market which is providing lucrative opportunities for growth. Further, the rise in demand for easy-to-use formulations especially in the geriatric population is providing lucrative opportunities to the buccal drug delivery system market.
The buccal route of administration is used in prolonged therapy and effective systematic deliveries. Buccal is considered to be convenient and accessible for the purpose of drug administration. The intention of buccal drug delivery systems is to deliver the drugs for achieving a systematic and local effect. The buccal drug delivery system even enables elimination of the pass metabolism which in turn allows drugs to be degraded easily. The quicker absorption and prevalence of minimum side-effects makes the system compatible with the need of end-users. This particular delivery system is one of the most used therapeutic options for use through buccal mucosal lines.
With the use of a buccal drug delivery system, the required therapeutic drug dose can be sent immediately to the human body and also gets readily absorbed in the plasma. The consistency of drugs can also be maintained all throughout the treatment duration. There are two major types of buccal dosage which include reservoir and matrix. The remarkable advantages have made the buccal drug delivery systems makes it popular in many developed as well as developing regions. The formulation administered through the buccal drug delivery system maintains close contact with the mucosa.
Request Sample:- Global buccal drug delivery systems
Market Dynamics
Drivers:
Buccal drug deliveries are gaining popularity in most of the regions owing to several reasons. The ease of administration associated with the buccal deliveries and inclination towards it is driving the market growth. The buccal deliveries are quickly absorbed in the patient’s body which makes it effective for the specified disease. The buccal deliveries also have minimized interaction with biofluid and side effects. The target site received a high concentration of the medicine which results in faster action. Along with these, the treatment regime also gets shorter which is why consumers are more inclined towards such systems.
The increasing research and development in the field of buccal drug deliveries are also promoting the growth of such delivery systems. There are many research studies that are focusing on the development of innovation of buccal deliveries method. The implementation of innovative and latest technologies is attractive various development in drug delivery methods. Novel formulations are required for the effective and fast treatment of chronic diseases.
Restraints:
Buccal medication delivery systems are costly to install, and many middle and small-scale users are unable to afford them. The buccal drug delivery systems have too many features, which makes them more expensive. In addition, the cost of upkeep is factored into the total cost.
Opportunities:
The increasing incidence of chronic diseases has led to an increase in the number of drug trials for various medicines. The rising number of demands of drug development has further provided lucrative opportunities for the market. Recently, the use of buccal drug delivery systems has been gaining popularity in multiple drug trials. There are many manufacturers who are investing hugely in drug delivery systems to increase the efficacy of drugs.
Challenges:
The buccal drug delivery systems require the passing of stringent regulations in order to be launched in the market. This system helps in the delivery of drugs, which can be further used in the treatment of various diseases. Thus, the approval of buccal drug delivery systems requires the passing of several stages in order to be proved safe for the required applications.
Segmentation Analysis
The global buccal drug delivery systems market has been segmented based on type, design, application, product, end-users, and regions.
By Type
The type segment includes buccal tablets and lozenges, sublingual films, and oral sprays. The buccal tablets and lozenges segment led the buccal drug delivery systems market with a market share of around 43.19% in 2021. This segment's growth is mainly attributed to the fact that they are mainly being preferred in buccal delivery due to the ease of administration. There is a high number of drug candidates who are required to get buccal formulations. It is also cost-effective as compared to the other type of buccal drug delivery systems.
By Design
The design segment includes reservoir and matrix. The reservoir segment led the buccal drug delivery systems market with a market share of around 66.34% in 2021. Reservoir buccal drug delivery systems enable the use of reservoir systems. The buccal path is customized into a reservoir system which consists of the cavity.
By Application
The application segment includes smoking cessation, pain management, angina pectoris, and others. The smoking cessation segment led the buccal drug delivery systems market with a market share of around 41.02% in 2021. Buccal deliveries for drugs are most effective for patients dealing with nicotine addiction. There are various studies that have proved that nicotine tablets and lozenges are the most preferable in the delivery of high concentration drugs.
By Product
The product segment includes bio-adhesive drug delivery systems and non-attached drug delivery systems. The bio-adhesive drug delivery systems segment led the buccal drug delivery systems market with a market share of around 67.11% in 2021. The bio-adhesive drug delivery systems are further segmented into chlorohexidine, hypromellose, hydrocortisone succinate, and miconazole. A bio-adhesive drug delivery system is considered to be useful in most diseases as it affects directly the target area.
By End-user
The end-user segment includes hospitals, specialty clinics, home care, and others. The hospital’s segment led the buccal drug delivery systems market with a market share of around 45.98% in 2021. Hospitals have a high number of patients visiting every day and thus the use of buccal drug delivery systems is dominant in the hospitals. Hospitals are also investing in such delivery systems for the treatment of the geriatric population.
By Regional Analysis
The regions analyzed for the buccal drug delivery systems market include North America, Europe, South America, Asia Pacific, and the Middle East, and Africa. North America region dominated the automated and closed-cell therapy processing market and held the 47.15% share of the market revenue in 2021.
Key Industry Players Analysis
To increase their market position in the global buccal drug delivery systems business, top companies are focusing on tactics such as adopting new technology, mergers & acquisitions, product developments, collaborations, and partnerships, joint ventures, etc.
Scope of the Report
Global Buccal Drug Delivery Systems Market by Type:
Global Buccal Drug Delivery Systems Market by Design:
Global Buccal Drug Delivery Systems Market by Application:
Global Buccal Drug Delivery Systems Market by Product:
Global Buccal Drug Delivery Systems Market by End-user:
Global Buccal Drug Delivery Systems Market by Region:
Global buccal drug delivery systems market is expected to reach USD 6.06 billion by 2028, at a CAGR of 9.80% from 2021 to 2028.
The regions analyzed for the buccal drug delivery systems market include North America, Europe, South America, Asia Pacific, and the Middle East, and Africa.
The global buccal drug delivery systems market has been segmented based on type, design, application, product, end-user, and regions.
Leading market players active in the global buccal drug delivery systems market are Pfizer Inc., Teva Pharmaceutical Inc., Ethypharm, Applied Pharma Research, Catalent, GlaxoSmithKline Plc., ARx LLC, Endo Pharmaceuticals, Cynapsus Therapeutics Inc., Generex Biotechnology, Medlab, Sanofi, Indivior PLC, Novartis AG, Bayer AG, Novo Nordisk A/S, F. Hoffmann La Roche Ltd., Dr. Reddy’s Laboratories Ltd., BioDelivery Sciences International Inc., AstraZeneca, NAPP Pharmaceutical Ltd. among others.
Rising demand for the effective administration of drugs and preference towards a buccal mode of delivery, are primarily driving the growth of the buccal drug delivery systems market. The absorption of the drugs administered through buccal delivery is usually quick and the most effective.
Manufacturers in the buccal drug delivery systems market are using advanced production technologies to incorporate better results, installation, and performance of the whole process. In addition, the rising number of investments will contribute to the demand for buccal drug delivery systems.
The pandemic has significantly affected several industries and has caused a worldwide economic slowdown. In order to stop the spread of the virus, the development of vaccines was the need of the hour. The buccal drug delivery systems market has decreased in recent times, owing to numerous factors such as delayed supply, limited workforce, and disturbed income patterns. The research and diagnostics laboratories were majorly involved in the development of vaccines and thus the buccal drug delivery systems market witnessed significant loss.
Based on the sales revenue, product offering, and regional presence, the companies are selected.
Political- The buccal drug delivery systems require the passing of stringent regulations in order to be launched in the market. This system helps in the delivery of drugs, which can be further used in the treatment of various diseases. Thus, the approval of buccal drug delivery systems requires the passing of several stages in order to be proved safe for the required applications.
Economic- The increasing incidence of chronic diseases has led to an increase in the number of drug trials for various medicines. The rising number of demands of drug development has further provided lucrative opportunities for the market. Recently, the use of buccal drug delivery systems has been gaining popularity in multiple drug trials. There are many manufacturers who are investing hugely in drug delivery systems to increase the efficacy of drugs. Buccal medication delivery systems are costly to install, and many middle and small-scale users are unable to afford them. The buccal drug delivery systems have too many features, which makes them more expensive. In addition, the cost of upkeep is factored into the total cost.
Social- The presence of established healthcare systems is one of the primary reasons for the development of buccal drug delivery systems. The manufacturers present in the region, are investing hugely in the buccal delivery and the development of new formulations. There is a larger number of geriatric populations which prefer to use the buccal drug delivery system market The availability of advanced technologies in the healthcare sector is propelling new growth opportunities for the market.
Technological- The increasing research and development in the field of buccal drug deliveries are also promoting the growth of such delivery systems. There are many research studies that are focusing on the development of innovation of buccal deliveries method. The implementation of innovative and latest technologies is attractive various development in drug delivery methods. Novel formulations are required for the effective and fast treatment of chronic diseases.
Environmental- There are several drugs that when exposed in the open air for a longer period of time cause pollution. Multiple diseases are also caused due to increasing pollution and changing lifestyles. Changing environment and increasing pollutants in the environment are causing diseases like skin cancer and lung and respiratory diseases because of the excessive inhalation of the polluted air. Many key players are working on finding these problems.
Legal- Avicanna Inc. which is a biopharmaceutical company focusing on the development, manufacturing, and commercialization of plant-derived cannabinoid-based pharmaceuticals is pleased to announce that it has filed a provisional patent application in the United States Patent and Trademark Office for a novel oral cannabinoid technology which is intended to be commercialized globally for medical and pharmaceutical applications including treatment of various neurological diseases and disorders.
List of Table
List of Figures